We are in the midst of a significant shift in pharmaceutical drug development, with many leading companies focusing increasingly on orphan drugs targeted at small niche markets.
For years, digital health has been heralded as the saviour of health services and the answer to patient engagement. Now the conversation is changing from what technology can do, to wha
Cat Oyler, Global Head of External Innovation Strategy and Operations at Johnson & Johnson (J&J), has an ambitious and compelling vision for the future of healthcare: a world withou
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.